Novan Announces Preclinical Data Demonstrating Immunomodulatory Effect In Vivo

Topical Application of SB414 Inhibited IL-17 in Psoriasis Mouse Model

Effect Relates to Multiple Inflammatory Skin Diseases

Novan, Inc. (“the Company” or “Novan”) (NASDAQ:NOVN) today announced preclinical data showing that the Company’s nitric oxide-releasing product candidate SB414 significantly (p<0.05) reduced composite psoriasis scores, which consist of erythema and plaque scores, and pro-inflammatory cytokines, including interleukin-17, or IL-17, in a psoriasis mouse model.